Test af tilsætning af MEDI4736 (Durvalumab) til kemoterapi før operation for patienter med højgradig øvre urinvejskræft
Et fase II/III-forsøg med MEDI4736 (Durvalumab) og kemoterapi til patienter med højgradig øvre del af urinrørskræft før nefroureterektomi
This phase II/III trial compares the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery in treating patients with upper urinary tract cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as methotrexate, vinblastine, doxorubicin, cisplatin, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Durvalumab in combination with chemotherapy before surgery may enhance the shrinking of the tumor compared to chemotherapy alone.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
- Medicin: Cisplatin
- Procedure: Biospecimen Collection
- Medicin: Methotrexate
- Procedure: Computed Tomography
- Procedure: Magnetic Resonance Imaging
- Medicin: Gemcitabine Hydrochloride
- Procedure: Therapeutic Conventional Surgery
- Procedure: Biopsy Procedure
- Biologisk: Durvalumab
- Medicin: Doxorubicin Hydrochloride
- Biologisk: Pegfilgrastim
- Medicin: Vinblastine Sulfate
Detaljeret beskrivelse
PRIMARY OBJECTIVES:
I. To compare event-free survival (EFS) between patients with upper tract urothelial cancer (UTUC) randomized to neoadjuvant accelerated methotrexate, vinblastine, Adriamycin, cisplatin (aMVAC) alone or in combination with durvalumab. (Cisplatin eligible patients [Arms A and B]) II. Evaluation of pathologic complete response at radical nephroureterectomy (RNU) (pathologic complete response [pCR], ypT0N0/Nx). (Cisplatin ineligible patients [Arm C]).
SECONDARY OBJECTIVES:
I. To assess pathologic complete response (pCR) at surgery. (Cisplatin eligible cohort) II. Event-free survival (EFS) will be evaluated for the cisplatin ineligible cohort as a secondary endpoint. (Cisplatin ineligible cohort) III. Overall survival in all, and by post chemotherapy response (ypT0N0, yp =< T1N0, yp >= T2Nany). (All patients) IV. To evaluate disease-free survival (DFS) in each arm of the trial separately. (All patients) V. To evaluate cancer-specific survival of patients in each arm of the trial separately. (All patients) VI. To evaluate renal function outcomes following systemic treatment and following surgery ([RNU) in each arm of the trial separately. (All patients) VII. To evaluate safety and tolerability of neoadjuvant aMVAC alone or in combination with durvalumab prior to RNU. (All patients)
OUTLINE: Patients eligible for cisplatin are randomized to Arms A or B. Patients ineligible for cisplatin are assigned to Arm C.
ARM A: Patients receive durvalumab intravenously (IV) over 60 minutes on day 1 of chemotherapy cycles 1 and 3. Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery.
ARM B: Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery.
ARM C: Patients receive durvalumab IV over 60 minutes on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery.
Patients also undergo tissue biopsy and blood sample collection on study, and computed tomography (CT) or magnetic resonance imaging (MRI) throughout the trial.
After completion of study treatment, patients are followed up within 30 days and then every 3-6 months for up to 5 years from study entry.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
Arizona
-
Kingman, Arizona, Forenede Stater, 86401
- Rekruttering
- Kingman Regional Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 702-384-0013
- E-mail: research@sncrf.org
-
Ledende efterforsker:
- Khawaja S. Jahangir
-
-
Arkansas
-
Fort Smith, Arkansas, Forenede Stater, 72903
- Suspenderet
- Mercy Hospital Fort Smith
-
Little Rock, Arkansas, Forenede Stater, 72205
- Aktiv, ikke rekrutterende
- University of Arkansas for Medical Sciences
-
-
California
-
Auburn, California, Forenede Stater, 95602
- Aktiv, ikke rekrutterende
- Sutter Auburn Faith Hospital
-
Berkeley, California, Forenede Stater, 94704
- Aktiv, ikke rekrutterende
- Alta Bates Summit Medical Center-Herrick Campus
-
Duarte, California, Forenede Stater, 91010
- Aktiv, ikke rekrutterende
- City of Hope Comprehensive Cancer Center
-
Fremont, California, Forenede Stater, 94538
- Aktiv, ikke rekrutterende
- Palo Alto Medical Foundation-Fremont
-
La Jolla, California, Forenede Stater, 92093
- Rekruttering
- UC San Diego Moores Cancer Center
-
Ledende efterforsker:
- Aditya Bagrodia
-
Kontakt:
- Site Public Contact
- Telefonnummer: 858-822-5354
- E-mail: cancercto@ucsd.edu
-
Modesto, California, Forenede Stater, 95355
- Aktiv, ikke rekrutterende
- Memorial Medical Center
-
Mountain View, California, Forenede Stater, 94040
- Aktiv, ikke rekrutterende
- Palo Alto Medical Foundation-Camino Division
-
Palo Alto, California, Forenede Stater, 94304
- Rekruttering
- Stanford Cancer Institute Palo Alto
-
Ledende efterforsker:
- Ali R. Khaki
-
Kontakt:
- Site Public Contact
- Telefonnummer: 650-498-7061
- E-mail: cancertrialsinfo@stanford.edu
-
Palo Alto, California, Forenede Stater, 94301
- Aktiv, ikke rekrutterende
- Palo Alto Medical Foundation Health Care
-
Roseville, California, Forenede Stater, 95661
- Aktiv, ikke rekrutterende
- Sutter Roseville Medical Center
-
Sacramento, California, Forenede Stater, 95816
- Aktiv, ikke rekrutterende
- Sutter Medical Center Sacramento
-
San Diego, California, Forenede Stater, 92103
- Rekruttering
- UC San Diego Medical Center - Hillcrest
-
Ledende efterforsker:
- Aditya Bagrodia
-
Kontakt:
- Site Public Contact
- E-mail: rhabbaba@health.ucsd.edu
-
San Francisco, California, Forenede Stater, 94115
- Aktiv, ikke rekrutterende
- California Pacific Medical Center-Pacific Campus
-
Santa Cruz, California, Forenede Stater, 95065
- Aktiv, ikke rekrutterende
- Palo Alto Medical Foundation-Santa Cruz
-
Santa Rosa, California, Forenede Stater, 95403
- Aktiv, ikke rekrutterende
- Sutter Pacific Medical Foundation
-
Sunnyvale, California, Forenede Stater, 94086
- Aktiv, ikke rekrutterende
- Palo Alto Medical Foundation-Sunnyvale
-
Vallejo, California, Forenede Stater, 94589
- Aktiv, ikke rekrutterende
- Sutter Solano Medical Center/Cancer Center
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Rekruttering
- UCHealth University of Colorado Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 720-848-0650
-
Ledende efterforsker:
- Elizabeth R. Kessler
-
Denver, Colorado, Forenede Stater, 80206
- Suspenderet
- UCHealth - Cherry Creek
-
Fort Collins, Colorado, Forenede Stater, 80524
- Rekruttering
- Poudre Valley Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 970-297-6150
-
Ledende efterforsker:
- Elizabeth R. Kessler
-
Fort Collins, Colorado, Forenede Stater, 80528
- Rekruttering
- Cancer Care and Hematology-Fort Collins
-
Kontakt:
- Site Public Contact
- E-mail: ecog.rss@jimmy.harvard.edu
-
Ledende efterforsker:
- Elizabeth R. Kessler
-
Greeley, Colorado, Forenede Stater, 80631
- Rekruttering
- UCHealth Greeley Hospital
-
Kontakt:
- Site Public Contact
- E-mail: ecog.rss@jimmy.harvard.edu
-
Ledende efterforsker:
- Elizabeth R. Kessler
-
Highlands Ranch, Colorado, Forenede Stater, 80129
- Rekruttering
- UCHealth Highlands Ranch Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 720-848-0650
-
Ledende efterforsker:
- Elizabeth R. Kessler
-
Lone Tree, Colorado, Forenede Stater, 80124
- Rekruttering
- UCHealth Lone Tree Health Center
-
Kontakt:
- Site Public Contact
- E-mail: ecog.rss@jimmy.harvard.edu
-
Ledende efterforsker:
- Elizabeth R. Kessler
-
Loveland, Colorado, Forenede Stater, 80538
- Rekruttering
- Medical Center of the Rockies
-
Kontakt:
- Site Public Contact
- Telefonnummer: 970-203-7083
-
Ledende efterforsker:
- Elizabeth R. Kessler
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20016
- Rekruttering
- Sibley Memorial Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 202-243-2373
- E-mail: jquiver1@jhmi.edu
-
Ledende efterforsker:
- Jean H. Hoffman-Censits
-
Washington D.C., District of Columbia, Forenede Stater, 20010
- Rekruttering
- MedStar Washington Hospital Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 202-877-8839
-
Ledende efterforsker:
- Suthee Rapisuwon
-
-
Florida
-
Jacksonville, Florida, Forenede Stater, 32224-9980
- Aktiv, ikke rekrutterende
- Mayo Clinic in Florida
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Rekruttering
- Emory University Hospital/Winship Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 404-778-1868
-
Ledende efterforsker:
- Jacqueline T. Brown
-
Atlanta, Georgia, Forenede Stater, 30308
- Rekruttering
- Emory University Hospital Midtown
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-946-7447
-
Ledende efterforsker:
- Jacqueline T. Brown
-
Atlanta, Georgia, Forenede Stater, 30342
- Rekruttering
- Emory Saint Joseph's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 404-851-7115
-
Ledende efterforsker:
- Jacqueline T. Brown
-
Decatur, Georgia, Forenede Stater, 30033
- Rekruttering
- Emory Decatur Hospital
-
Ledende efterforsker:
- Jacqueline T. Brown
-
Kontakt:
- Site Public Contact
- Telefonnummer: 440-778-1868
- E-mail: clinicaltrialsoncology@dekalbmedical.org
-
-
Idaho
-
Nampa, Idaho, Forenede Stater, 83687
- Rekruttering
- Saint Alphonsus Cancer Care Center-Nampa
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Ledende efterforsker:
- Elie G. Dib
-
-
Illinois
-
Alton, Illinois, Forenede Stater, 62002
- Suspenderet
- OSF Saint Anthony's Health Center
-
Barrington, Illinois, Forenede Stater, 60010
- Rekruttering
- Advocate Good Shepherd Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-842-4847
-
Ledende efterforsker:
- Thomas J. Saphner
-
Bloomington, Illinois, Forenede Stater, 61704
- Aktiv, ikke rekrutterende
- Illinois CancerCare-Bloomington
-
Burr Ridge, Illinois, Forenede Stater, 60527
- Aktiv, ikke rekrutterende
- Loyola Center for Health at Burr Ridge
-
Canton, Illinois, Forenede Stater, 61520
- Aktiv, ikke rekrutterende
- Illinois CancerCare-Canton
-
Carbondale, Illinois, Forenede Stater, 62902
- Suspenderet
- Memorial Hospital of Carbondale
-
Carterville, Illinois, Forenede Stater, 62918
- Rekruttering
- SIH Cancer Institute
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 618-985-3333
- E-mail: clinical.research@sih.net
-
Carthage, Illinois, Forenede Stater, 62321
- Aktiv, ikke rekrutterende
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Forenede Stater, 62801
- Suspenderet
- Centralia Oncology Clinic
-
Chicago, Illinois, Forenede Stater, 60657
- Rekruttering
- Advocate Illinois Masonic Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 773-296-5360
-
Ledende efterforsker:
- Thomas J. Saphner
-
Crystal Lake, Illinois, Forenede Stater, 60014
- Rekruttering
- AMG Crystal Lake - Oncology
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-929-6129
- E-mail: advocateresearch@advocate.com
-
Ledende efterforsker:
- Thomas J. Saphner
-
Danville, Illinois, Forenede Stater, 61832
- Rekruttering
- Carle at The Riverfront
-
Ledende efterforsker:
- Prem Sobti
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-mail: Research@Carle.com
-
Decatur, Illinois, Forenede Stater, 62526
- Rekruttering
- Cancer Care Specialists of Illinois - Decatur
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Decatur, Illinois, Forenede Stater, 62526
- Suspenderet
- Decatur Memorial Hospital
-
Dixon, Illinois, Forenede Stater, 61021
- Aktiv, ikke rekrutterende
- Illinois CancerCare-Dixon
-
Downers Grove, Illinois, Forenede Stater, 60515
- Rekruttering
- Advocate Good Samaritan Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-275-1270
- E-mail: Barbara.barhamand@advocatehealth.com
-
Ledende efterforsker:
- Thomas J. Saphner
-
Effingham, Illinois, Forenede Stater, 62401
- Rekruttering
- Carle Physician Group-Effingham
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-mail: Research@carle.com
-
Ledende efterforsker:
- Prem Sobti
-
Effingham, Illinois, Forenede Stater, 62401
- Rekruttering
- Crossroads Cancer Center
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Elgin, Illinois, Forenede Stater, 60123
- Rekruttering
- Advocate Sherman Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-429-2907
-
Ledende efterforsker:
- Thomas J. Saphner
-
Eureka, Illinois, Forenede Stater, 61530
- Aktiv, ikke rekrutterende
- Illinois CancerCare-Eureka
-
Galesburg, Illinois, Forenede Stater, 61401
- Suspenderet
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, Forenede Stater, 61401
- Aktiv, ikke rekrutterende
- Illinois CancerCare-Galesburg
-
Hazel Crest, Illinois, Forenede Stater, 60429
- Rekruttering
- Advocate South Suburban Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 708-799-9995
-
Ledende efterforsker:
- Thomas J. Saphner
-
Homer Glen, Illinois, Forenede Stater, 60491
- Aktiv, ikke rekrutterende
- Loyola Medicine Homer Glen
-
Kewanee, Illinois, Forenede Stater, 61443
- Aktiv, ikke rekrutterende
- Illinois CancerCare-Kewanee Clinic
-
Libertyville, Illinois, Forenede Stater, 60048
- Rekruttering
- AMG Libertyville - Oncology
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-929-6129
- E-mail: advocateresearch@advocatehealth.com
-
Ledende efterforsker:
- Thomas J. Saphner
-
Macomb, Illinois, Forenede Stater, 61455
- Aktiv, ikke rekrutterende
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Forenede Stater, 61938
- Rekruttering
- Carle Physician Group-Mattoon/Charleston
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-mail: Research@carle.com
-
Ledende efterforsker:
- Prem Sobti
-
Maywood, Illinois, Forenede Stater, 60153
- Aktiv, ikke rekrutterende
- Loyola University Medical Center
-
Melrose Park, Illinois, Forenede Stater, 60160
- Aktiv, ikke rekrutterende
- Marjorie Weinberg Cancer Center at Loyola-Gottlieb
-
Mount Vernon, Illinois, Forenede Stater, 62864
- Rekruttering
- SSM Health Good Samaritan
-
Ledende efterforsker:
- Jay W. Carlson
-
Kontakt:
- Site Public Contact
- Telefonnummer: 618-899-1894
- E-mail: gayla.hall@ssmhealth.com
-
O'Fallon, Illinois, Forenede Stater, 62269
- Rekruttering
- Cancer Care Center of O'Fallon
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Oak Lawn, Illinois, Forenede Stater, 60453-2699
- Rekruttering
- Advocate Christ Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-323-8622
-
Ledende efterforsker:
- Thomas J. Saphner
-
Ottawa, Illinois, Forenede Stater, 61350
- Aktiv, ikke rekrutterende
- Illinois CancerCare-Ottawa Clinic
-
Park Ridge, Illinois, Forenede Stater, 60068
- Rekruttering
- Advocate Lutheran General Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-384-3621
-
Ledende efterforsker:
- Thomas J. Saphner
-
Pekin, Illinois, Forenede Stater, 61554
- Aktiv, ikke rekrutterende
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Forenede Stater, 61636
- Suspenderet
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Forenede Stater, 61615
- Aktiv, ikke rekrutterende
- Illinois CancerCare-Peoria
-
Peru, Illinois, Forenede Stater, 61354
- Suspenderet
- Valley Radiation Oncology
-
Peru, Illinois, Forenede Stater, 61354
- Aktiv, ikke rekrutterende
- Illinois CancerCare-Peru
-
Princeton, Illinois, Forenede Stater, 61356
- Aktiv, ikke rekrutterende
- Illinois CancerCare-Princeton
-
Springfield, Illinois, Forenede Stater, 62702
- Rekruttering
- Southern Illinois University School of Medicine
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-545-7929
-
Springfield, Illinois, Forenede Stater, 62702
- Rekruttering
- Springfield Clinic
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-444-7541
-
Springfield, Illinois, Forenede Stater, 62781
- Suspenderet
- Springfield Memorial Hospital
-
Urbana, Illinois, Forenede Stater, 61801
- Rekruttering
- Carle Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-mail: Research@carle.com
-
Ledende efterforsker:
- Prem Sobti
-
Washington, Illinois, Forenede Stater, 61571
- Aktiv, ikke rekrutterende
- Illinois CancerCare - Washington
-
-
Indiana
-
Richmond, Indiana, Forenede Stater, 47374
- Aktiv, ikke rekrutterende
- Reid Health
-
-
Iowa
-
Ames, Iowa, Forenede Stater, 50010
- Aktiv, ikke rekrutterende
- Mary Greeley Medical Center
-
Ames, Iowa, Forenede Stater, 50010
- Aktiv, ikke rekrutterende
- McFarland Clinic - Ames
-
Bettendorf, Iowa, Forenede Stater, 52722
- Rekruttering
- University of Iowa Healthcare Cancer Services Quad Cities
-
Ledende efterforsker:
- Fernando Maciel Barbosa
-
Kontakt:
- Site Public Contact
- Telefonnummer: 563-355-7733
- E-mail: katherine-daprile@uiowa.edu
-
Boone, Iowa, Forenede Stater, 50036
- Aktiv, ikke rekrutterende
- McFarland Clinic - Boone
-
Fort Dodge, Iowa, Forenede Stater, 50501
- Aktiv, ikke rekrutterende
- McFarland Clinic - Trinity Cancer Center
-
Iowa City, Iowa, Forenede Stater, 52242
- Rekruttering
- University of Iowa/Holden Comprehensive Cancer Center
-
Ledende efterforsker:
- Fernando Maciel Barbosa
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-237-1225
-
Jefferson, Iowa, Forenede Stater, 50129
- Aktiv, ikke rekrutterende
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Forenede Stater, 50158
- Aktiv, ikke rekrutterende
- McFarland Clinic - Marshalltown
-
-
Kansas
-
Garden City, Kansas, Forenede Stater, 67846
- Suspenderet
- Central Care Cancer Center - Garden City
-
Great Bend, Kansas, Forenede Stater, 67530
- Suspenderet
- Central Care Cancer Center - Great Bend
-
-
Kentucky
-
Lexington, Kentucky, Forenede Stater, 40536
- Rekruttering
- University of Kentucky/Markey Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 859-257-3379
-
Ledende efterforsker:
- Patrick J. Hensley
-
-
Louisiana
-
Baton Rouge, Louisiana, Forenede Stater, 70809
- Rekruttering
- Mary Bird Perkins Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 225-215-1353
- E-mail: clinicalresearch@marybird.com
-
Ledende efterforsker:
- Victor T. Lin
-
Metairie, Louisiana, Forenede Stater, 70006
- Rekruttering
- East Jefferson General Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 504-210-3539
- E-mail: emede1@lsuhsc.edu
-
Ledende efterforsker:
- Rajasree P. Chowdry
-
Metairie, Louisiana, Forenede Stater, 70006
- Rekruttering
- LSU Healthcare Network / Metairie Multi-Specialty Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 504-210-3539
- E-mail: emede1@lsuhsc.edu
-
Ledende efterforsker:
- Rajasree P. Chowdry
-
Metairie, Louisiana, Forenede Stater, 70002
- Rekruttering
- Mary Bird Perkins Cancer Center - Metairie
-
Ledende efterforsker:
- Victor T. Lin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 504-584-6990
-
New Orleans, Louisiana, Forenede Stater, 70112
- Rekruttering
- University Medical Center New Orleans
-
Kontakt:
- Site Public Contact
- Telefonnummer: 504-210-3539
- E-mail: emede1@lsuhsc.edu
-
Ledende efterforsker:
- Rajasree P. Chowdry
-
-
Maine
-
Augusta, Maine, Forenede Stater, 04330
- Rekruttering
- Harold Alfond Center for Cancer Care
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-626-4855
-
Ledende efterforsker:
- Erin Adler
-
Biddeford, Maine, Forenede Stater, 04005
- Suspenderet
- MaineHealth Maine Medical Center - Biddeford
-
Sanford, Maine, Forenede Stater, 04073
- Rekruttering
- MaineHealth Cancer Care Center of York County
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-459-1600
-
Ledende efterforsker:
- Erin Adler
-
Sanford, Maine, Forenede Stater, 04073
- Rekruttering
- MaineHealth Cancer Care and IV Therapy - Sanford
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-396-8670
- E-mail: clinicalresearch@mainehealth.org
-
Ledende efterforsker:
- Erin Adler
-
Scarborough, Maine, Forenede Stater, 04074
- Rekruttering
- MaineHealth Maine Medical Center- Scarborough
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-396-8670
- E-mail: clinicalresearch@mainehealth.org
-
Ledende efterforsker:
- Erin Adler
-
South Portland, Maine, Forenede Stater, 04106
- Rekruttering
- MaineHealth Cancer Care and IV Therapy - South Portland
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-396-8670
- E-mail: clinicalresearch@mainehealth.org
-
Ledende efterforsker:
- Erin Adler
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21287
- Rekruttering
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 410-955-8804
- E-mail: jhcccro@jhmi.edu
-
Ledende efterforsker:
- Jean H. Hoffman-Censits
-
-
Massachusetts
-
Worcester, Massachusetts, Forenede Stater, 01655
- Rekruttering
- UMass Memorial Medical Center - University Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 508-856-3216
- E-mail: cancer.research@umassmed.edu
-
Ledende efterforsker:
- Kriti Mittal
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48106
- Rekruttering
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Ledende efterforsker:
- Elie G. Dib
-
Brighton, Michigan, Forenede Stater, 48114
- Rekruttering
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Ledende efterforsker:
- Elie G. Dib
-
Brighton, Michigan, Forenede Stater, 48114
- Rekruttering
- Trinity Health Medical Center - Brighton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Ledende efterforsker:
- Elie G. Dib
-
Canton, Michigan, Forenede Stater, 48188
- Rekruttering
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Ledende efterforsker:
- Elie G. Dib
-
Canton, Michigan, Forenede Stater, 48188
- Rekruttering
- Trinity Health Medical Center - Canton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Ledende efterforsker:
- Elie G. Dib
-
Chelsea, Michigan, Forenede Stater, 48118
- Rekruttering
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Ledende efterforsker:
- Elie G. Dib
-
Chelsea, Michigan, Forenede Stater, 48118
- Rekruttering
- Chelsea Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Ledende efterforsker:
- Elie G. Dib
-
Clarkston, Michigan, Forenede Stater, 48346
- Rekruttering
- Hematology Oncology Consultants-Clarkston
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Ledende efterforsker:
- Elie G. Dib
-
Clarkston, Michigan, Forenede Stater, 48346
- Suspenderet
- Newland Medical Associates-Clarkston
-
Flint, Michigan, Forenede Stater, 48503
- Rekruttering
- Genesys Hurley Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 810-762-8038
- E-mail: wstrong@ghci.org
-
Ledende efterforsker:
- Elie G. Dib
-
Flint, Michigan, Forenede Stater, 48503
- Rekruttering
- Hurley Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 810-762-8038
- E-mail: wstrong@ghci.org
-
Ledende efterforsker:
- Elie G. Dib
-
Flint, Michigan, Forenede Stater, 48503
- Suspenderet
- Genesee Hematology Oncology PC
-
Flint, Michigan, Forenede Stater, 48503
- Rekruttering
- Cancer Hematology Centers - Flint
-
Kontakt:
- Site Public Contact
- Telefonnummer: 810-762-8038
- E-mail: wstrong@ghci.org
-
Ledende efterforsker:
- Elie G. Dib
-
Livonia, Michigan, Forenede Stater, 48154
- Suspenderet
- Hope Cancer Clinic
-
Livonia, Michigan, Forenede Stater, 48154
- Rekruttering
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Ledende efterforsker:
- Elie G. Dib
-
Macomb, Michigan, Forenede Stater, 48044
- Rekruttering
- Henry Ford Saint John Hospital - Macomb Medical
-
Ledende efterforsker:
- Elie G. Dib
-
Kontakt:
- Site Public Contact
- Telefonnummer: 313-343-3166
- E-mail: kforman1@hfhs.org
-
Pontiac, Michigan, Forenede Stater, 48341
- Rekruttering
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Ledende efterforsker:
- Elie G. Dib
-
Pontiac, Michigan, Forenede Stater, 48341
- Rekruttering
- Michigan Healthcare Professionals Pontiac
-
Ledende efterforsker:
- Elie G. Dib
-
Kontakt:
- Site Public Contact
- Telefonnummer: 248-858-6215
- E-mail: Emily.Crofts@trinity-health.org
-
Pontiac, Michigan, Forenede Stater, 48341
- Rekruttering
- Trinity Health IHA Medical Group-Alice Gustafson Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Ledende efterforsker:
- Elie G. Dib
-
Saginaw, Michigan, Forenede Stater, 48604
- Suspenderet
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Forenede Stater, 48601
- Rekruttering
- MyMichigan Medical Center Saginaw
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Ledende efterforsker:
- Elie G. Dib
-
Tawas City, Michigan, Forenede Stater, 48764
- Rekruttering
- MyMichigan Medical Center Tawas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Ledende efterforsker:
- Elie G. Dib
-
West Branch, Michigan, Forenede Stater, 48661
- Suspenderet
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Forenede Stater, 48106
- Rekruttering
- Huron Gastroenterology PC
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Ledende efterforsker:
- Elie G. Dib
-
Ypsilanti, Michigan, Forenede Stater, 48197
- Rekruttering
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Ledende efterforsker:
- Elie G. Dib
-
-
Minnesota
-
Burnsville, Minnesota, Forenede Stater, 55337
- Suspenderet
- Fairview Ridges Hospital
-
Burnsville, Minnesota, Forenede Stater, 55337
- Suspenderet
- Minnesota Oncology - Burnsville
-
Cambridge, Minnesota, Forenede Stater, 55008
- Suspenderet
- Cambridge Medical Center
-
Coon Rapids, Minnesota, Forenede Stater, 55433
- Rekruttering
- Mercy Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Ledende efterforsker:
- David M. King
-
Edina, Minnesota, Forenede Stater, 55435
- Suspenderet
- Fairview Southdale Hospital
-
Edina, Minnesota, Forenede Stater, 55435
- Rekruttering
- Minnesota Oncology - Edina
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Ledende efterforsker:
- David M. King
-
Fridley, Minnesota, Forenede Stater, 55432
- Aktiv, ikke rekrutterende
- Unity Hospital
-
Maple Grove, Minnesota, Forenede Stater, 55369
- Suspenderet
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, Forenede Stater, 55109
- Rekruttering
- Minnesota Oncology Hematology PA-Maplewood
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Ledende efterforsker:
- David M. King
-
Maplewood, Minnesota, Forenede Stater, 55109
- Suspenderet
- Saint John's Hospital - Healtheast
-
Minneapolis, Minnesota, Forenede Stater, 55407
- Suspenderet
- Abbott-Northwestern Hospital
-
Minneapolis, Minnesota, Forenede Stater, 55415
- Suspenderet
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Forenede Stater, 55454
- Suspenderet
- Health Partners Inc
-
Monticello, Minnesota, Forenede Stater, 55362
- Suspenderet
- Monticello Cancer Center
-
New Ulm, Minnesota, Forenede Stater, 56073
- Suspenderet
- New Ulm Medical Center
-
Princeton, Minnesota, Forenede Stater, 55371
- Suspenderet
- Fairview Northland Medical Center
-
Robbinsdale, Minnesota, Forenede Stater, 55422
- Suspenderet
- North Memorial Medical Health Center
-
Rochester, Minnesota, Forenede Stater, 55905
- Rekruttering
- Mayo Clinic in Rochester
-
Kontakt:
- Site Public Contact
- Telefonnummer: 855-776-0015
-
Ledende efterforsker:
- Lance C. Pagliaro
-
Saint Louis Park, Minnesota, Forenede Stater, 55416
- Rekruttering
- Park Nicollet Clinic - Saint Louis Park
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Ledende efterforsker:
- David M. King
-
Saint Paul, Minnesota, Forenede Stater, 55101
- Rekruttering
- Regions Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Ledende efterforsker:
- David M. King
-
Saint Paul, Minnesota, Forenede Stater, 55102
- Suspenderet
- United Hospital
-
Shakopee, Minnesota, Forenede Stater, 55379
- Suspenderet
- Saint Francis Regional Medical Center
-
Stillwater, Minnesota, Forenede Stater, 55082
- Rekruttering
- Lakeview Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Ledende efterforsker:
- David M. King
-
Waconia, Minnesota, Forenede Stater, 55387
- Suspenderet
- Ridgeview Medical Center
-
Willmar, Minnesota, Forenede Stater, 56201
- Suspenderet
- Rice Memorial Hospital
-
Woodbury, Minnesota, Forenede Stater, 55125
- Rekruttering
- Minnesota Oncology Hematology PA-Woodbury
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Ledende efterforsker:
- David M. King
-
Wyoming, Minnesota, Forenede Stater, 55092
- Suspenderet
- Fairview Lakes Medical Center
-
-
Missouri
-
Ballwin, Missouri, Forenede Stater, 63011
- Suspenderet
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Bolivar, Missouri, Forenede Stater, 65613
- Suspenderet
- Central Care Cancer Center - Bolivar
-
Cape Girardeau, Missouri, Forenede Stater, 63703
- Rekruttering
- Saint Francis Medical Center
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 573-334-2230
- E-mail: sfmc@sfmc.net
-
Cape Girardeau, Missouri, Forenede Stater, 63703
- Suspenderet
- Mercy Cancer Center - Cape Girardeau
-
Farmington, Missouri, Forenede Stater, 63640
- Rekruttering
- Parkland Health Center - Farmington
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
Jefferson City, Missouri, Forenede Stater, 65109
- Suspenderet
- MU Health Care Goldschmidt Cancer Center
-
Joplin, Missouri, Forenede Stater, 64804
- Suspenderet
- Freeman Health System
-
Joplin, Missouri, Forenede Stater, 64804
- Suspenderet
- Mercy Hospital Joplin
-
Rolla, Missouri, Forenede Stater, 65401
- Suspenderet
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla, Missouri, Forenede Stater, 65401
- Suspenderet
- Phelps Health Delbert Day Cancer Institute
-
Saint Joseph, Missouri, Forenede Stater, 64506
- Suspenderet
- Heartland Regional Medical Center
-
Sainte Genevieve, Missouri, Forenede Stater, 63670
- Rekruttering
- Sainte Genevieve County Memorial Hospital
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
Springfield, Missouri, Forenede Stater, 65804
- Suspenderet
- Mercy Hospital Springfield
-
Springfield, Missouri, Forenede Stater, 65807
- Suspenderet
- CoxHealth South Hospital
-
St Louis, Missouri, Forenede Stater, 63128
- Rekruttering
- Mercy Hospital South
-
Ledende efterforsker:
- Jay W. Carlson
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-525-6042
- E-mail: Danielle.Werle@mercy.net
-
St Louis, Missouri, Forenede Stater, 63141
- Rekruttering
- Mercy Hospital Saint Louis
-
Ledende efterforsker:
- Jay W. Carlson
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-251-7066
-
St Louis, Missouri, Forenede Stater, 63109
- Suspenderet
- Mercy Infusion Center - Chippewa
-
St Louis, Missouri, Forenede Stater, 63131
- Rekruttering
- Missouri Baptist Medical Center
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
Sullivan, Missouri, Forenede Stater, 63080
- Rekruttering
- Missouri Baptist Sullivan Hospital
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
Washington, Missouri, Forenede Stater, 63090
- Suspenderet
- Mercy Hospital Washington
-
-
Nevada
-
Las Vegas, Nevada, Forenede Stater, 89102
- Suspenderet
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Forenede Stater, 89183
- Suspenderet
- OptumCare Cancer Care at Fort Apache
-
-
New Jersey
-
Hackensack, New Jersey, Forenede Stater, 07601
- Afsluttet
- Hackensack University Medical Center
-
Livingston, New Jersey, Forenede Stater, 07039
- Rekruttering
- Cooperman Barnabas Medical Center
-
Ledende efterforsker:
- Saum B. Ghodoussipour
-
Kontakt:
- Site Public Contact
- Telefonnummer: 973-322-5200
-
New Brunswick, New Jersey, Forenede Stater, 08903
- Rekruttering
- Rutgers Cancer Institute of New Jersey
-
Ledende efterforsker:
- Saum B. Ghodoussipour
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-235-7356
-
Toms River, New Jersey, Forenede Stater, 08755
- Rekruttering
- Community Medical Center
-
Ledende efterforsker:
- Saum B. Ghodoussipour
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-557-8294
- E-mail: Lennette.Gonzales@rwjbh.org
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87106
- Rekruttering
- University of New Mexico Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 505-925-0348
- E-mail: HSC-ClinicalTrialInfo@salud.unm.edu
-
Ledende efterforsker:
- Amy C. Tarnower
-
-
New York
-
Buffalo, New York, Forenede Stater, 14263
- Aktiv, ikke rekrutterende
- Roswell Park Cancer Institute
-
-
North Carolina
-
Clinton, North Carolina, Forenede Stater, 28328
- Rekruttering
- Southeastern Medical Oncology Center-Clinton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 919-587-9084
- E-mail: jfields@cancersmoc.com
-
Ledende efterforsker:
- Samer S. Kasbari
-
Goldsboro, North Carolina, Forenede Stater, 27534
- Rekruttering
- Southeastern Medical Oncology Center-Goldsboro
-
Kontakt:
- Site Public Contact
- Telefonnummer: 919-587-9084
- E-mail: jfields@cancersmoc.com
-
Ledende efterforsker:
- Samer S. Kasbari
-
Jacksonville, North Carolina, Forenede Stater, 28546
- Rekruttering
- Southeastern Medical Oncology Center-Jacksonville
-
Ledende efterforsker:
- Samer S. Kasbari
-
Kontakt:
- Site Public Contact
- Telefonnummer: 910-587-9084
- E-mail: jfields@cancersmoc.com
-
Winston-Salem, North Carolina, Forenede Stater, 27157
- Aktiv, ikke rekrutterende
- Wake Forest University Health Sciences
-
-
Ohio
-
Centerville, Ohio, Forenede Stater, 45459
- Rekruttering
- Miami Valley Hospital South
-
Kontakt:
- Site Public Contact
- Telefonnummer: 937-528-2900
- E-mail: clinical.trials@daytonncorp.org
-
Ledende efterforsker:
- Tarek M. Sabagh
-
Centerville, Ohio, Forenede Stater, 45459
- Aktiv, ikke rekrutterende
- Dayton Physicians LLC-Miami Valley South
-
Dayton, Ohio, Forenede Stater, 45409
- Rekruttering
- Miami Valley Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 937-528-2900
- E-mail: clinical.trials@daytonncorp.org
-
Ledende efterforsker:
- Tarek M. Sabagh
-
Dayton, Ohio, Forenede Stater, 45415
- Rekruttering
- Miami Valley Hospital North
-
Kontakt:
- Site Public Contact
- Telefonnummer: 937-528-2900
- E-mail: clinical.trials@daytonncorp.org
-
Ledende efterforsker:
- Tarek M. Sabagh
-
Dayton, Ohio, Forenede Stater, 45409
- Rekruttering
- Premier Blood and Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 937-276-8320
-
Ledende efterforsker:
- Tarek M. Sabagh
-
Dayton, Ohio, Forenede Stater, 45415
- Aktiv, ikke rekrutterende
- Dayton Physician LLC - Englewood
-
Findlay, Ohio, Forenede Stater, 45840
- Aktiv, ikke rekrutterende
- Armes Family Cancer Center
-
Franklin, Ohio, Forenede Stater, 45005-1066
- Rekruttering
- Atrium Medical Center-Middletown Regional Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 937-528-2900
- E-mail: clinical.trials@daytonncorp.org
-
Ledende efterforsker:
- Tarek M. Sabagh
-
Franklin, Ohio, Forenede Stater, 45005
- Aktiv, ikke rekrutterende
- Dayton Physicians LLC-Atrium
-
Greenville, Ohio, Forenede Stater, 45331
- Rekruttering
- Miami Valley Cancer Care and Infusion
-
Ledende efterforsker:
- Tarek M. Sabagh
-
Kontakt:
- Site Public Contact
- Telefonnummer: 937-569-7515
-
Kettering, Ohio, Forenede Stater, 45409
- Aktiv, ikke rekrutterende
- Greater Dayton Cancer Center
-
Kettering, Ohio, Forenede Stater, 45429
- Aktiv, ikke rekrutterende
- Kettering Medical Center
-
Springfield, Ohio, Forenede Stater, 45504
- Suspenderet
- Springfield Regional Cancer Center
-
Sylvania, Ohio, Forenede Stater, 43560
- Rekruttering
- ProMedica Flower Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 419-824-1842
- E-mail: PCIOncResearch@promedica.org
-
Ledende efterforsker:
- Jeffrey H. Muler
-
Troy, Ohio, Forenede Stater, 45373
- Rekruttering
- Upper Valley Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 937-528-2900
- E-mail: clinical.trials@daytonncorp.org
-
Ledende efterforsker:
- Tarek M. Sabagh
-
-
Oklahoma
-
Lawton, Oklahoma, Forenede Stater, 73505
- Rekruttering
- Cancer Centers of Southwest Oklahoma Research
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-231-4440
-
Ledende efterforsker:
- Adanma Anji Ayanambakkam Attanathi
-
Oklahoma City, Oklahoma, Forenede Stater, 73104
- Rekruttering
- University of Oklahoma Health Sciences Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 405-271-8777
- E-mail: ou-clinical-trials@ouhsc.edu
-
Ledende efterforsker:
- Adanma Anji Ayanambakkam Attanathi
-
Oklahoma City, Oklahoma, Forenede Stater, 73120
- Suspenderet
- Mercy Hospital Oklahoma City
-
-
Pennsylvania
-
Erie, Pennsylvania, Forenede Stater, 16505
- Rekruttering
- UPMC Hillman Cancer Center Erie
-
Ledende efterforsker:
- Leonard J. Appleman
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-864-7716
- E-mail: ClinicalResearchServices@upmc.edu
-
Greensburg, Pennsylvania, Forenede Stater, 15601
- Rekruttering
- UPMC Cancer Centers - Arnold Palmer Pavilion
-
Kontakt:
- Site Public Contact
- Telefonnummer: 724-838-1900
-
Ledende efterforsker:
- Leonard J. Appleman
-
Hershey, Pennsylvania, Forenede Stater, 17033-0850
- Rekruttering
- Penn State Milton S Hershey Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 717-531-3779
- E-mail: CTO@hmc.psu.edu
-
Ledende efterforsker:
- Monika Joshi
-
Monroeville, Pennsylvania, Forenede Stater, 15146
- Rekruttering
- UPMC Hillman Cancer Center - Monroeville
-
Ledende efterforsker:
- Leonard J. Appleman
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-864-7716
- E-mail: ClinicalResearchServices@upmc.edu
-
Philadelphia, Pennsylvania, Forenede Stater, 19107
- Rekruttering
- Thomas Jefferson University Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 215-600-9151
- E-mail: ONCTrialNow@jefferson.edu
-
Ledende efterforsker:
- William J. Tester
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Rekruttering
- University of Pennsylvania/Abramson Cancer Center
-
Ledende efterforsker:
- Ronac Mamtani
-
Kontakt:
- Site Public Contact
- Telefonnummer: 215-349-8245
- E-mail: PMCancerResearch@pennmedicine.upenn.edu
-
Pittsburgh, Pennsylvania, Forenede Stater, 15237
- Rekruttering
- UPMC-Passavant Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-367-6454
-
Ledende efterforsker:
- Leonard J. Appleman
-
Pittsburgh, Pennsylvania, Forenede Stater, 15243
- Rekruttering
- UPMC-Saint Clair Hospital Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-502-3920
-
Ledende efterforsker:
- Leonard J. Appleman
-
Pittsburgh, Pennsylvania, Forenede Stater, 15232
- Rekruttering
- UPMC Hillman Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-647-8073
-
Ledende efterforsker:
- Leonard J. Appleman
-
Washington, Pennsylvania, Forenede Stater, 15301
- Rekruttering
- UPMC Cancer Center-Washington
-
Kontakt:
- Site Public Contact
- E-mail: ecog.rss@jimmy.harvard.edu
-
Ledende efterforsker:
- Leonard J. Appleman
-
West Reading, Pennsylvania, Forenede Stater, 19611
- Rekruttering
- Reading Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 610-988-9323
-
Ledende efterforsker:
- Terrence P. Cescon
-
-
South Carolina
-
Charleston, South Carolina, Forenede Stater, 29425
- Aktiv, ikke rekrutterende
- Medical University of South Carolina
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75390
- Rekruttering
- UT Southwestern/Simmons Cancer Center-Dallas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 214-648-7097
- E-mail: canceranswerline@UTSouthwestern.edu
-
Ledende efterforsker:
- Vitaly Margulis
-
Dallas, Texas, Forenede Stater, 75235
- Rekruttering
- Parkland Memorial Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 214-590-5582
- E-mail: canceranswerline@UTSouthwestern.edu
-
Ledende efterforsker:
- Vitaly Margulis
-
Dallas, Texas, Forenede Stater, 75237
- Suspenderet
- UT Southwestern Simmons Cancer Center - RedBird
-
Fort Worth, Texas, Forenede Stater, 76104
- Rekruttering
- UT Southwestern/Simmons Cancer Center-Fort Worth
-
Kontakt:
- Site Public Contact
- Telefonnummer: 214-648-7097
- E-mail: canceranswerline@UTSouthwestern.edu
-
Ledende efterforsker:
- Vitaly Margulis
-
Richardson, Texas, Forenede Stater, 75080
- Rekruttering
- UT Southwestern Clinical Center at Richardson/Plano
-
Kontakt:
- Site Public Contact
- Telefonnummer: 972-669-7044
- E-mail: Suzanne.cole@utsouthwestern.edu
-
Ledende efterforsker:
- Vitaly Margulis
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98195
- Rekruttering
- University of Washington Medical Center - Montlake
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-804-8824
-
Ledende efterforsker:
- Petros Grivas
-
Seattle, Washington, Forenede Stater, 98109
- Rekruttering
- Fred Hutchinson Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-804-8824
-
Ledende efterforsker:
- Petros Grivas
-
-
West Virginia
-
Charleston, West Virginia, Forenede Stater, 25304
- Rekruttering
- Vandalia Health/CAMC Institute for Academic Medicine
-
Ledende efterforsker:
- Kok Hoe Chan
-
Kontakt:
- Site Public Contact
- Telefonnummer: 304-388-9944
- E-mail: CAMCClinicalTrials@vandaliahealth.org
-
-
Wisconsin
-
Appleton, Wisconsin, Forenede Stater, 54911
- Rekruttering
- ThedaCare Regional Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-364-3604
- E-mail: ResearchDept@thedacare.org
-
Ledende efterforsker:
- Matthias Weiss
-
Burlington, Wisconsin, Forenede Stater, 53105
- Rekruttering
- Aurora Cancer Care-Southern Lakes VLCC
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Ledende efterforsker:
- Thomas J. Saphner
-
Eau Claire, Wisconsin, Forenede Stater, 54701
- Rekruttering
- Marshfield Medical Center-EC Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Ledende efterforsker:
- Seth O. Fagbemi
-
Germantown, Wisconsin, Forenede Stater, 53022
- Rekruttering
- Aurora Health Care Germantown Health Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Ledende efterforsker:
- Thomas J. Saphner
-
Grafton, Wisconsin, Forenede Stater, 53024
- Rekruttering
- Aurora Cancer Care-Grafton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Ledende efterforsker:
- Thomas J. Saphner
-
Green Bay, Wisconsin, Forenede Stater, 54311
- Rekruttering
- Aurora BayCare Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Ledende efterforsker:
- Thomas J. Saphner
-
Kenosha, Wisconsin, Forenede Stater, 53142
- Rekruttering
- Aurora Cancer Care-Kenosha South
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Ledende efterforsker:
- Thomas J. Saphner
-
Marinette, Wisconsin, Forenede Stater, 54143
- Rekruttering
- Aurora Bay Area Medical Group-Marinette
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Ledende efterforsker:
- Thomas J. Saphner
-
Marshfield, Wisconsin, Forenede Stater, 54449
- Rekruttering
- Marshfield Medical Center-Marshfield
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Ledende efterforsker:
- Seth O. Fagbemi
-
Milwaukee, Wisconsin, Forenede Stater, 53209
- Rekruttering
- Aurora Cancer Care-Milwaukee
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Ledende efterforsker:
- Thomas J. Saphner
-
Milwaukee, Wisconsin, Forenede Stater, 53215
- Rekruttering
- Aurora Saint Luke's Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Ledende efterforsker:
- Thomas J. Saphner
-
Milwaukee, Wisconsin, Forenede Stater, 53233
- Rekruttering
- Aurora Sinai Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Ledende efterforsker:
- Thomas J. Saphner
-
Minocqua, Wisconsin, Forenede Stater, 54548
- Rekruttering
- Marshfield Medical Center - Minocqua
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Ledende efterforsker:
- Seth O. Fagbemi
-
Mukwonago, Wisconsin, Forenede Stater, 53149
- Rekruttering
- ProHealth D N Greenwald Center
-
Kontakt:
- Site Public Contact
- E-mail: research.institute@phci.org
-
Ledende efterforsker:
- Timothy R. Wassenaar
-
New Richmond, Wisconsin, Forenede Stater, 54017
- Suspenderet
- Cancer Center of Western Wisconsin
-
Oconomowoc, Wisconsin, Forenede Stater, 53066
- Rekruttering
- ProHealth Oconomowoc Memorial Hospital
-
Ledende efterforsker:
- Timothy R. Wassenaar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 262-928-7878
-
Oshkosh, Wisconsin, Forenede Stater, 54904
- Rekruttering
- Vince Lombardi Cancer Clinic - Oshkosh
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Ledende efterforsker:
- Thomas J. Saphner
-
Racine, Wisconsin, Forenede Stater, 53406
- Rekruttering
- Aurora Cancer Care-Racine
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Ledende efterforsker:
- Thomas J. Saphner
-
Rice Lake, Wisconsin, Forenede Stater, 54868
- Rekruttering
- Marshfield Medical Center-Rice Lake
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Ledende efterforsker:
- Seth O. Fagbemi
-
Sheboygan, Wisconsin, Forenede Stater, 53081
- Rekruttering
- Vince Lombardi Cancer Clinic-Sheboygan
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Ledende efterforsker:
- Thomas J. Saphner
-
Stevens Point, Wisconsin, Forenede Stater, 54482
- Rekruttering
- Marshfield Medical Center-River Region at Stevens Point
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Ledende efterforsker:
- Seth O. Fagbemi
-
Summit, Wisconsin, Forenede Stater, 53066
- Rekruttering
- Aurora Medical Center in Summit
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Ledende efterforsker:
- Thomas J. Saphner
-
Two Rivers, Wisconsin, Forenede Stater, 54241
- Rekruttering
- Vince Lombardi Cancer Clinic-Two Rivers
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Ledende efterforsker:
- Thomas J. Saphner
-
Waukesha, Wisconsin, Forenede Stater, 53188
- Rekruttering
- ProHealth Waukesha Memorial Hospital
-
Ledende efterforsker:
- Timothy R. Wassenaar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 262-928-7632
-
Waukesha, Wisconsin, Forenede Stater, 53188
- Rekruttering
- UW Cancer Center at ProHealth Care
-
Ledende efterforsker:
- Timothy R. Wassenaar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 262-928-5539
- E-mail: Chanda.miller@phci.org
-
Waupaca, Wisconsin, Forenede Stater, 54981
- Rekruttering
- ThedaCare Cancer Care - Waupaca
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-364-3605
- E-mail: ResearchDept@thedacare.org
-
Ledende efterforsker:
- Matthias Weiss
-
Wauwatosa, Wisconsin, Forenede Stater, 53226
- Rekruttering
- Aurora Cancer Care-Milwaukee West
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Ledende efterforsker:
- Thomas J. Saphner
-
West Allis, Wisconsin, Forenede Stater, 53227
- Rekruttering
- Aurora West Allis Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-mail: ncorp@aurora.org
-
Ledende efterforsker:
- Thomas J. Saphner
-
Weston, Wisconsin, Forenede Stater, 54476
- Rekruttering
- Marshfield Medical Center - Weston
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Ledende efterforsker:
- Seth O. Fagbemi
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
STEP 1 REGISTRATION AND RANDOMIZATION
-
Patients must be >= 18 years of age
-
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
-
Patient must have a diagnosis of high grade upper tract urothelial carcinoma expected within 14 weeks (98 days) prior to registration/randomization with one of the following:
-
Biopsy (gold standard, preferred) and either upper urinary tract mass on cross-sectional imaging or tumor directly visualized during upper urinary tract endoscopy
-
High grade cytology and clinically estimated invasive upper urinary tract mass on cross-sectional imaging (e.g., including presence of tumor-related hydronephrosis) or tumor directly visualized during upper urinary tract endoscopy
-
NOTE: Universal histologic testing of UTUC with additional studies, such as immunohistochemistry and/or microsatellite instability, is strongly recommended to identify patients with high probability of Lynch-related or other germline mutation related cancers whom clinicians should refer for genetic counseling and germline testing (this is not required for eligibility)
- Due to the anatomy of upper urinary tract and lack of muscularis propria, pathologic evidence of cT2 on biopsy is usually not possible
-
-
-
Patients must not have any component of small cell/neuroendocrine carcinoma. Other histologic subtypes (variants) are permitted provided the half or predominant (>= 50%) subtype is conventional urothelial carcinoma
-
Leukocytes >= 3,000/mcL (obtained =< 14 days prior to registration/randomization)
-
Platelets >= 100,000/mcL (obtained =< 14 days prior to registration/randomization)
-
Total bilirubin =< 1.2 mg/dL (or ≤ 2 mg/dL for patients with Gilbert's disease)
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2 x institutional ULN (obtained =< 14 days prior to registration/randomization)
-
Hemoglobin (Hgb) >= 9 g/dL (obtained =< 14 days prior to registration/randomization)
- NOTE: Packed red blood transfusion is allowed to achieve this parameter as per treating investigator
-
Patients must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy. A patient of childbearing potential is defined as any patient, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
Patients of childbearing potential and sexually active patients must not expect to conceive or father children, either by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse from the time of registration, while on study treatment and for at least 6 months after the last dose of protocol treatment
-
Patients must have no evidence of metastatic disease or clinically enlarged regional lymph nodes (>= 1.5 cm short axis) on imaging required within 28 days prior to registration (Non-regional findings >=1.5 cm short axis that in the opinion of the investigator are not concerning for involvement based on radiographic characteristics, chronicity, avidity on positron emission tomography (PET) scan or other imaging or other criteria can be eligible based on investigator discretion).
- NOTE: Patients with elevated alkaline phosphatase, calcium or suspicious bone pain/tenderness can also undergo baseline bone scan to evaluate for bone metastasis at the discretion of local provider.
-
Patient must meet below criteria for prior/current malignancy history:
-
Non-urothelial cancer malignancy history:
-
Patient must not have another active (or within two years) second malignancy other than resected non-melanoma skin cancers, resected in situ breast, cervical or other in situ carcinoma, and either clinically insignificant per the investigator (e.g. =< Gleason 3+4) on active surveillance (or watchful waiting) or previously treated prostate cancer with no rising prostate specific antigen (PSA) and no plan to treat
- NOTE: Patients with prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
-
Urothelial cancer malignancy history:
- Patient may have a history of resectable urothelial cancer as long as patients meet one of the following:
- T0, Ta or Tis at any time
- T1-4a N0 and no evidence of disease (NED) for more than 2 years from the latest therapy [e.g., radical surgery, transurethral resection of bladder tumor (TURBT), radiation, chemotherapy (neoadjuvant or adjuvant, or with radiation)]. Prior systemic immune checkpoint inhibitor is not allowed.
- Patient with history of >= pT4b, N+, and/or M1 UC is not eligible.
- NOTE: Patients in whom concomitant or prior bladder/urethra predominant (>= 50%) urothelial carcinoma have been surgically resected and demonstrated to be only Ta or carcinoma in situ (CIS) (< cT1 N0) are eligible regardless of time elapsed
-
-
-
Patient must not have any uncontrolled illness including, but not limited to, ongoing or active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice), symptomatic congestive heart failure (CHF), myocardial infarction (MI) or unstable angina pectoris, significant uncontrolled cardiac arrhythmia, clinically relevant liver cirrhosis, interstitial lung disease, or psychiatric illness/social situations in the three months prior to registration that would limit compliance with study requirements
-
Patient must not have received prior radiation therapy to >= 25% of the bone marrow for other diseases
-
Patient must not have received prior systemic anthracycline therapy
- NOTE: Patients who have received prior intravesical therapy at any time for non-muscle invasive urothelial carcinoma of the bladder are eligible
-
Patient must not have either history of or active autoimmune disease requiring immunosuppressive therapy within 2 years prior to registration/randomization or any history of inflammatory bowel disease (inflammatory bowel disease [IBD], e.g. ulcerative colitis, or Crohn's disease), neuromuscular autoimmune condition, immune-related pneumonitis or interstitial lung disease. Patients with well-controlled hyper/hypothyroidism, celiac controlled by diet alone, diabetes mellitus type I, vitiligo, alopecia, psoriasis, eczema, lichen planus, or similar skin/mucosa condition are eligible
-
Patient must not be on or have used immunosuppressive medication within 14 days prior to the first dose of durvalumab. The following are exceptions to this criterion and are allowed:
- Intranasal, inhaled, intra-auricular, topical steroids, or local steroid injections (e.g. intra-articular injection
- Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent at the time of enrollment
- Steroids as pre-medications for hypersensitivity reactions (e.g. computed tomography [CT] pre-medication)
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration/randomization are eligible for this trial
- NOTE: These patients must be stable on their anti-retroviral regimen with evidence of at least two undetectable viral loads within the past 6 months on the same regimen; the most recent undetectable viral load must be within the past 12 weeks. They must have a CD4 count of greater than 250 cells/mcL over the past 6 months on this same anti-retroviral regimen and must not have had a CD4 count < 200 cells/mcL over the past 2 years, unless it was deemed related to the cancer and/or chemotherapy induced bone marrow suppression. They must not be currently receiving prophylactic therapy for an opportunistic infection and must not have had an opportunistic infection within the past 6 months
- NOTE: For patients who have received chemotherapy in the past 6 months, a CD4 count < 250 cells/mcL during chemotherapy is permitted as long as viral loads were undetectable during this same chemotherapy. They must have an undetectable viral load and a CD4 count >= 250 cells/mcL within 7 days of registration/randomization
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- NOTE: Testing for HIV, hepatitis B or hepatitis C is not required unless clinically indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and have undetectable viral load. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
-
Patient must not have received live attenuated vaccine within 30 days prior to the first dose of durvalumab, while on protocol treatment and within 30 days after the last dose of durvalumab
-
Patient must not have had a major surgical procedure within 28 days prior to registration/randomization
- NOTE: Cystoscopy/ureteroscopy/TURBT, stent placement or nephrostomy tube is not considered major surgery
-
Patient must not have history of allogenic organ transplantation
-
Patient must have a body weight of > 30 kg
-
Patient must have life expectancy of >= 12 weeks
-
Patient must have creatinine clearance > 15 ml/min as estimated by Cockcroft-Gault formula or glomerular filtration rate (GFR) > 15 ml/min/1.73m^2 within 28 days prior to registration/randomization
-
NOTE: Patients will be assigned to cisplatin-ineligible and cisplatin-eligible cohorts based on their creatinine clearance, Eastern Cooperative Oncology Group (ECOG) performance status, and grade (if any) of peripheral neuropathy and/or hearing loss in keeping with recommended cisplatin contraindications. Patients who are cisplatin-eligible will be randomized to either Arm A or Arm B and patients who are cisplatin-ineligible will be registered to Arm C
-
Patients that meet any of the following four criteria will be registered to the cisplatin-ineligible Arm C if they meet other eligibility criteria:
- Creatinine clearance > 15 ml/min and =< 50 ml/min (estimated by Cockcroft-Gault formula) or GFR > 15ml/min/1.73m^2 and ≤ 50 ml/min/1.73 m^2
- Hearing loss >= 3
- Neuropathy >= 2
- ECOG performance status 2
-
In addition, the patient must have an absolute neutrophil count (ANC) >= 1,000/mcL obtained =< 14 days prior to registration
-
Patients that meet all of the following four criteria will be randomized to the cisplatin-eligible Arm A or Arm B:
- Creatinine clearance > 50ml/min (estimated by Cockcroft-Gault formula) or GFR > 50ml/min/1.73m^2
- ECOG performance status 0-1
- Hearing loss grade 0-2
- Neuropathy 0-1
-
In addition, the patient must have an absolute neutrophil count (ANC) >= 1,500/mcL obtained =< 14 days prior to randomization
-
Also, the patient must have left ventricular ejection fraction (LVEF) >= 50% by (either multigated acquisition scan [MUGA] or 2-D echocardiogram) obtained within obtained within 28 days prior to randomization
-
-
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Arm A (durvalumab, chemotherapy)
Patients receive durvalumab IV over 60 minutes on day 1 of chemotherapy cycles 1 and 3. Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery. Patients also undergo tissue biopsy and blood sample collection on study, and CT or MRI throughout the trial. |
Given IV
Andre navne:
Undergo blood sample collection
Andre navne:
Given IV
Andre navne:
Undergo CT
Andre navne:
Undergo MRI
Andre navne:
Undergo surgery Undergo tissue biopsy
Andre navne:
Given IV
Andre navne:
Given Iv
Andre navne:
Given via injection
Andre navne:
Given Iv
Andre navne:
|
|
Aktiv komparator: Arm B (chemotherapy)
Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery. Patients also undergo tissue biopsy and blood sample collection on study, and CT or MRI throughout the trial. |
Given IV
Andre navne:
Undergo blood sample collection
Andre navne:
Given IV
Andre navne:
Undergo CT
Andre navne:
Undergo MRI
Andre navne:
Undergo surgery Undergo tissue biopsy
Andre navne:
Given Iv
Andre navne:
Given via injection
Andre navne:
Given Iv
Andre navne:
|
|
Eksperimentel: Arm C (durvalumab, gemcitabine hydrochloride)
Patients receive durvalumab IV over 60 minutes on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery. Patients also undergo tissue biopsy and blood sample collection on study, and CT or MRI throughout the trial. |
Undergo blood sample collection
Andre navne:
Undergo CT
Andre navne:
Undergo MRI
Andre navne:
Given IV
Andre navne:
Undergo surgery Undergo tissue biopsy
Andre navne:
Given IV
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Event-free survival (EFS) (Cisplatin eligible cohort: Arms A and B)
Tidsramme: From registration/randomization to the earliest of systemic recurrence outside urinary tract, cancer progression, or death from any cause, assessed up to 5 years
|
Disease progression prior to surgery or omission of surgery due to unresectable tumors, muscle-invasive cancer or disease recurring outside of the bladder, urethra, or contralateral upper tract are considered as events for EFS. |
From registration/randomization to the earliest of systemic recurrence outside urinary tract, cancer progression, or death from any cause, assessed up to 5 years
|
|
Pathologic complete response (pCR) (Cisplatin ineligible cohort: Arm C)
Tidsramme: At surgery
|
Will assess pathologic complete response at surgery (pCR, pT0N0/Nx) by local pathology review. Patients who drop out prior to surgery or who have unknown response status will be considered as non-responders. |
At surgery
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
pCR (Cisplatin-kvalificeret kohorte: arm A og B)
Tidsramme: Op til 5 år
|
Op til 5 år
|
|
|
EFS (cisplatin-ineligible cohort: Arm C)
Tidsramme: From registration/randomization to the earliest of systemic recurrence outside urinary tract, cancer progression, or death from any cause, assessed up to 5 years
|
Will be characterized using the Kaplan-Meier method. |
From registration/randomization to the earliest of systemic recurrence outside urinary tract, cancer progression, or death from any cause, assessed up to 5 years
|
|
Overall survival (OS) (All Patients)
Tidsramme: From registration/randomization to death from any cause, assessed up to 5 years
|
OS will be evaluated by arm, post chemotherapy response (ypCR, stage yp =< T1N0, yp >= T2N0), as well as stage (ypCR and > ypCR) within and across treatment arms. Will be estimated using Kaplan-Meier method. |
From registration/randomization to death from any cause, assessed up to 5 years
|
|
Urothelial cancer-free survival or disease-free survival (All Patients)
Tidsramme: From the date of surgery to the earlier of a return of upper tract urothelial cancer (UTUC) or death from any cause, assessed up to 5 years
|
A return of UTUC includes non-muscle invasive recurrences, pathologic T2 or higher muscle-invasive recurrences specifically in the urinary tract, metastatic disease outside the urinary tract, or death. Patients alive without documented UTUC will be censored at the date of last disease assessment. |
From the date of surgery to the earlier of a return of upper tract urothelial cancer (UTUC) or death from any cause, assessed up to 5 years
|
|
Cancer-specific survival (All Patients)
Tidsramme: From registration/randomization to death due to cancer; deaths due to other causes will be counted as competing events, assessed up to 5 years
|
Will be analyzed using Gray's method and cumulative incidence estimates will be reported. |
From registration/randomization to death due to cancer; deaths due to other causes will be counted as competing events, assessed up to 5 years
|
|
Renal function outcomes following systemic treatment and following radical nephroureterectomy (All Patients)
Tidsramme: Post chemotherapy and post surgery
|
The proportion of patients with renal insufficiency (creatinine [CrCl] < 60 ml/min) post chemotherapy and post nephroureterectomy as well as the proportion of patients with renal function improvement (CrCl < 60 ml/min at baseline and CrCl >= 60 ml/min on study) will be reported along with exact binomial confidence intervals. The distribution of changes in renal function post chemotherapy as well as post surgery from baseline will also be reported. The analysis of renal function outcomes will be performed among patients who receive at least one dose of study therapy. |
Post chemotherapy and post surgery
|
|
Incidence of adverse events (All Patients)
Tidsramme: Up to 30 days post surgery
|
Toxicity will be evaluated in all treated patients. |
Up to 30 days post surgery
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Jean H Hoffman-Censits, ECOG-ACRIN Cancer Research Group
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Aminosyrer, peptider og proteiner
- Proteiner
- Svovlforbindelser
- Organiske kemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Undersøgelsesteknikker
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og procedurer
- Diagnose
- Kirurgiske procedurer, operative
- Cytologiske teknikker
- Cytodiagnose
- Kulbrinter
- Kulbrinter, cyklisk
- Kulhydrater
- Alkaloider
- Polycykliske aromatiske kulbrinter
- Kulbrinter, aromatisk
- Polycykliske forbindelser
- Glycosider
- Indoler
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Uorganiske kemikalier
- Klorforbindelser
- Nitrogenforbindelser
- Deoxycytidin
- Cytidin
- Pyrimidin -nukleosider
- Pyrimidiner
- Elementer
- Metaller
- Diagnostiske teknikker, kirurgisk
- Kemiteknikker, analytisk
- Spektrumanalyse
- Pterins
- Pteridiner
- Metaller, tung
- Vinca alkaloider
- Secologanin tryptamin alkaloider
- Indole alkaloider
- Indolizidiner
- Indolizines
- Aminopterin
- Anthracycliner
- Naphthacenes
- Aminoglycosider
- Immunoglobulin -isotyper
- Sulfider
- Anioner
- Ioner
- Elektrolytter
- Hydrogensulfid
- Platinforbindelser
- Daunorubicin
- Overgangselementer
- Gemcitabin
- Methotrexat
- Doxorubicin
- Immunoglobulin G
- Cisplatin
- Vinblastin
- 1,2-diaminocyclohexanplatin II-citrat
- Biopsi
- Håndtering af eksemplar
- Magnetisk resonansspektroskopi
- Durvalumab
- Disulfider
- Platinum
- Merphos
- Pegfilgrastim
- Pegyleret granulocytkolonistimulerende faktor
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- NCI-2020-09850
- U10CA180820 (U.S. NIH-bevilling/kontrakt)
- NCI-2020-09850 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- EA8192 (Anden identifikator: CTEP)
- EA8192 (Anden identifikator: ECOG-ACRIN Cancer Research Group)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .